Background
The transcription factor, CCAAT/Enhancer binding protein β (C/EBPβ) is an important mediator of mammary development [
1,
2] and breast tumorigenesis [
3,
4]. Encoded by an intronless gene, C/EBPβ is expressed as several distinct protein isoforms (LAP1, LAP2 and LIP) whose expression is tightly regulated by the differential use of a number of in-frame translation start sites [
5‐
7]. All of the C/EBPβ isoforms share the same C-terminal DNA binding and leucine zipper dimerization domains, but LIP lacks all of the N-terminal transactivation domain and much of the inhibitory domains. Consequently, LIP can act as a dominant-negative [
5] to inhibit gene transcription or as an activator of transcription, depending upon the nature of its interaction with other C/EBP family members and transcription factors [
8‐
11].
The LIP and LAP isoforms may thus have potentially opposing actions in cellular proliferation and differentiation and increases in the LIP/LAP ratio are known to be associated with tumorigenesis and metastasis. For example, overexpression of LIP in the rodent mammary gland leads to hyperplasia and tumor formation [
12]. In humans, the LIP isoform is strongly expressed in a percentage of aggressive human breast tumors that are estrogen receptor negative, aneuploid, highly proliferative and associated with a poor prognosis [
13,
14]. In metastatic breast cancer cells, an increase in the LIP/LAP ratio has been linked to a loss in the TGFβ-dependent cytostatic response and a more aggressive phenotype [
15]. The C/EBPβ isoforms thereby play an important role in high grade, metastatic breast cancer and the LIP/LAP ratio is a critical determinant in the aggressiveness of the disease.
It is therefore imperative, that we better understand the molecular mechanisms regulating LIP expression and the biological significance of the LIP/LAP ratio in breast cancer. Growth factor signaling pathways, such as the insulin-like growth factor-1 receptor (IGF-1R) [
16] and the epidermal growth factor receptor (EGFR) signaling cascades [
17] have been implicated in the development of aggressive, metastatic breast cancer. IGF-1R signaling contributes to breast cancer progression and recurrence in part by increasing cell survival via mechanisms that include suppression of anoikis [
18‐
21]. Anoikis is an induction of apoptosis that occurs in cells upon loss of cellular adhesion and is one of the hallmarks of metastasis [
22]. C/EBPβ has also been shown to play a role in cell survival; specifically, of hepatic cells [
23], keratinocytes [
24], and macrophages [
25], but has not yet been associated with suppression of anoikis. Moreover, it is also not known whether LIP plays a specific role to increase the survival of breast cancer cells. To better understand the molecular mechanisms that regulate LIP expression in metastatic breast cancer, we set out to determine in mammary epithelial cells whether IGF-1R signaling leads to an increase in LIP expression and whether LIP plays a role in IGF-1R mediated suppression of anoikis.
Numerous studies have demonstrated that the actions of IGF-1R are linked to that of EGFR in epithelial mammary cells to synergistically drive cellular proliferation [
26‐
30]. Additional reports have characterized a relationship between IGF-1R and EGFR signaling in aggressive, drug-resistant breast cancer cells and have speculated that IGF-1R signaling plays a role in the development of gefitinib resistant EGFR tumors [
31]. Because our previous study [
32], demonstrated that LIP expression is increased by EGFR signaling, this led us to question, and to address in this study whether IGF-1R signaling can solely regulate LIP expression and whether crosstalk and activation of the EGF receptor is required. Along these lines, a recent study showed how changes in the LIP/LAP ratio downstream of HER2 provide evasion to oncogene induced senescence and TGFβ cytostasis [
33]. These authors showed that changes in LIP/LAP ratio, in an AKT dependent manner, support evasion of a tumor suppressor mechanism in metastatic breast cancer cells [
33]. Similarly, an earlier study demonstrated that HER2 expression can lead to survival from anoikis in MCF10 and HMEC cells [
34].
Our data demonstrate that IGF-1R signaling regulates LIP expression in an EGFR independent manner to increase LIP expression and the LIP/LAP ratio in mammary epithelial cells. Although crosstalk between IGF-1R signaling and EGFR signaling is detectable in MCF10A cells, this crosstalk is not required for the IGF-1 mediated regulation of LIP expression. Rather, the critical regulator of IGF-1 induced LIP expression appears to be EGFR-independent, Akt activity. Our data also demonstrate that a biological action of LIP is to increase cell survival by suppression of anoikis which may occur in either an IGF-1R mediated context or in a manner independent of IGF-1R signaling. Taken together, the accumulated evidence discussed above, as well as our current data suggest that LIP expression may be an important downstream target of EGFR, ErbB2 and IGF-1R signaling in breast cancer.
Discussion
Our data, as well as that from others, suggest that oncogenic signaling pathways such as IGF-1R, EGFR [
32], and ErbB2 [
33] regulate increases in LIP expression and the LIP/LAP ratio. IGF-1R, EGFR and ErbB2 and are also critical regulators of tumorigenesis and can regulate cellular survival of anoikis [
34,
41]. IGF-1R signaling is known to play an important role in the resistance of cells to apoptosis and this anti-apoptotic effect is most strongly observed during anchorage-independent conditions (reviewed in [
42] and in metastatic breast cancer cells [
43,
44] The survival of cells in suspension, or the ability to suppress anoikis, is a critical step in the progression of invasive cancer because metastatic cells must survive under anchorage-independent conditions as they move from the primary tumor to distant sites. The molecular mechanisms that regulate anoikis in invasive cancer cells are poorly understood, but we have demonstrated that loss of C/EBPβ expression renders cells more susceptible to anoikis, even in the presence of IGF-1R signaling. Moreover, LIP overexpression protects cells from anoikis. Our study is the first to document a role for C/EBPβ in the survival of mammary epithelial cells under anchorage-independent growth conditions. The biological significance of elevated LIP expression as a consequence of IGF-1R receptor signaling holds important implications for the LIP/LAP ratio as a critical mediator of anchorage-independent growth in breast cancer.
Taken together, C/EBPβ-LIP appears to be an important downstream target for EGFR, ErbB2 and IGF-1R signaling, and particpates in the regulation cell survival and apoptosis. This survival mechanism may actually be quite universal and not unique to breast cells. For example, macrophages require C/EBPβ for survival in response to Myc/Raf transformation [
25] and hepatic stellate cells that are DNA damaged via CCl4 induced free radical formation [
23] also need C/EBPβ for survival. In keratinocytes that have suffered DNA damage, C/EBPβ promotes cell survival by reducing p53 expression and activity [
45]. Reduced levels of C/EBPβ can thereby sensitize cells to apoptosis and this has been observed both in our anoikis model (Figure
6A) and in C/EBPβ null mice which display resistance to DMBA-induced skin tumorigenesis [
24].
Numerous parallels exist between the biological effects of IGF-1R signaling and that of LIP overexpression. For instance, both the IGF-1/insulin receptor families and the C/EBPβ isoforms play important roles in cellular processes that regulate mammary development and breast cancer such as cell cycle control, proliferation, and differentiation. As an example, cell cycle entry and progression to the restriction point in late G
1 is controlled by growth factors, such as IGF-1; however the C/EBPβ isoforms also interact with or regulate similar cell cycle proteins such as p53 [
46], Rb [
47,
48] CDK2, cyclin A, cyclin E [
49] cyclin D1 [
50] p21Cip1, [
51], and p15INK4b [
15].
In regards to development, inhibition of IGF-1R signaling or knockdown of C/EBPβ expression disrupts mammary gland development. For example, mammary gland development is restricted in both IGF-1 null mice [
52] and in IGF-1R-null mice [
53]. Similar phenotypes are observed in the C/EBPβ null mouse, where deletion of the C/EBPβ isoforms leads to defective mammary gland development and reduced milk production [
1,
2]. Conversely, the activation or elevation of IGF-1R or LIP expression induces mammary proliferation and tumorigenesis. For example, overexpression of IGF-1R in the mouse mammary gland leads to tumorigenesis [
54‐
58] while in a similar fashion, transgenic expression of LIP in mouse mammary glands induces hyperproliferation and tumorigenesis [
12].
Moreover, in women, elevated LIP or IGF-1R expression are independently associated with breast cancer. Approximately 23% of aggressive breast cancers contain elevated LIP and this increase in LIP is associated with reduced estrogen and progesterone receptor expression and an otherwise poor prognosis [
13]. Both the IGF-1R and insulin receptor are activated and expressed at elevated levels in breast cancer [
16,
59]. In fact, patients with type 2 diabetes mellitus are suspected to be at increased risk of developing breast cancer [
60]. When considering the fact that LIP expression is regulated by IGF-1R signaling, and that numerous biological similarities exist between LIP overexpression and IGF-1R signaling, one can only speculate that LIP may in part, be a critical mediator of many of the downstream effects of IGF-1R signaling
Although our study focused on the IGF-1R regulation of LIP and LAP expression; the reverse has also been observed, and IGF-1 expression and/or activity has been shown to be regulated by the LIP and LAP isoforms in macrophages, hepatocytes, and osteoblasts (Reviewed in [
4]). With the exception of our current study in the mammary epithelial cell line MCF10A, little is known about IGF-1 and LIP/LAP interactions in breast epithelial cells. In bone marrow derived macrophages isolated from the C/EBPβ K/O mouse, IGF-1 expression is moderately decreased in response to the loss of C/EBPβ expression [
25]. Similarly, in hepatocytes, the addition of C/EBPβ-LAP in the human hepatoma cell line Hep3B increases IGF-1 expression [
61]. Overexpression of LIP alone appears to have no effect on IGF-1 promoter activity, but does abolish the transactivation induced by LAP [
61]. Moreover, C/EBPβ is believed to play a role in the proliferation and differentiation of osteoblasts via regulation of IGF-1 and studies have shown that the protein levels and DNA binding activity of the C/EBPβ isoforms, LAP1, LAP2 and LIP are elevated in proliferating osteoblasts (MC3T3-E1 cells) and down regulated upon differentiation [
62]. In light of these studies and our recent data, we speculate that the C/EBPβ-LIP and LAP isoforms participate in a feedback loop to regulate IGF-1 signaling; however, this hypothesis will require further experimentation.
Conclusions
Previously we demonstrated in MCF10As that EGFR signaling increases expression of the C/EBPβ-LIP isoform and that this regulation is dependent upon Erk1/2 activity [
32]. We now show that IGF-1 and insulin signaling regulate LIP expression in MCF10A cells, and that Akt activity, rather than Erk1/2 is a critical determinant for IGF-1R induced LIP expression. In some cellular contexts, cross talk has been shown to occur between the IGF-1 receptor and the EGF receptor (EGFR) during mediation of IGF-1 signaling [
26,
27,
29,
63]. The mechanism of crosstalk may involve the IGF-1 stimulated cleavage and solubilization of EGFR pro-ligands which lead to EGFR activation [
26] or the direct interaction of IGF-1R with EGFR to form EGFR-IGF-1R hetero-oligomers [
29]. Regardless of the mechanism at work in our study, crosstalk between IGF-1 and EGFR is not necessary for the regulation of LIP expression by IGF-1. The reasons for this may be explained by the observation that PI3K/Akt pathway and Ras/Erk1/2 pathways downstream of IGF-1 signaling are often functionally dissociated [
26,
29]. IGF-1 induced Erk1/2 activity can be predominantly activated by the transactivation of EGFR in response to IGF-1 while Akt activation is independent of EGFR activity [
26,
29]. Our data clearly show that IGF-1 mediated increases in LIP expression are not regulated by EGFR dependent Erk1/2 activity, but rather by IGF-1 induced Akt activity. The mechanism by which Akt activates LIP translation and expression remain to be elucidated.
Methods
Cell Culture
Cultured mammary epithelial cells, MCF10A, were grown in Dulbecco modified Eagle medium (DMEM)-F12 (Invitrogen, USA) supplemented with 5% donor horse serum (Invitrogen, USA), 20 ng/ml of recombinant human EGF (Invitrogen, USA), 10 μg/ml of bovine pancreatic insulin (Sigma, USA), 100 ng/ml of cholera toxin (Sigma, USA), 0.5 μg/ml of hydrocortisone (Sigma, USA), and 5 μg/ml of gentamycin sulfate (Invitrogen, USA). MCF7 cells were grown in Eagle's Minimum Essential Medium (MEM) (Mediatech, USA) supplemented with 0.01 mg/ml bovine insulin and 10% fetal bovine serum (Hyclone, USA). C/EBPβ null cells were culture in Hepes buffered, Dulbecco modified Eagle medium (DMEM)-F12 (Invitrogen, USA) supplemented with 2% adult bovine serum (Invitrogen, USA), 5 ng/ml of recombinant human EGF (Invitrogen, USA), 10 μg/ml of bovine pancreatic insulin (Sigma, USA) and 5 μg/ml gentamycin sulfate.
Suspension Culture/Anoikis Assay
To knock down C/EBPβ expression, C/EBPβ (Tet-On) and control TRIPZ™lentiviral shRNAmir constructs (Open Biosystem, USA) were stably transduced into MCF-10A cells by infection and puromycin selection. Prior to suspension culture, the cells were treated with Doxycycline (1 μg/ml) for 2 days to activate shRNA expression, followed by one more day of Dox treatment in serum free conditions to synchronize the cells and to generate a maximal knockdown of C/EBPβ expression. To prevent adherence, cells were transferred to Costar 6 well ultra low attachment plates (20,000 cells/well) or to 1% agar coated plates (500,000 cells/10 cm dish) for 24, 48 and 96 hrs in the presence or absence of IGF-1 (2.6 nM and 39 nM). After 24 hrs, suspended cells were transferred to standard 6 well cell culture plates and permitted to adhere to analyze survival via clonogenic outgrowth for two weeks followed by staining with crystal violet. Flow cytometry was conducted on cells collected at 48 and 96 hrs of suspension culture. Briefly, suspended cells were collected by centrifuge at 1000 rpm for 5 min. To prevent clustering, cells were digested in 1× trypsin at 37°C for 5 min, followed by washing with HBSS. Cells were then resuspended in (0.6% NP-40, 3.7% Formalin, 11% Hoechst 33258 in PBS) for Flow cytometry. Cell death was analyzed by measuring the sub-G
1 cell cycle fraction. LIP was overexpressed in MCF-10A cells using a pEIZ (HIV-Zsgreen) lentiviral construct driven by the EF-alpha 1 promoter (kindly provided by Dr. Zena Werb [
40]) and cells were sorted. Annexin V-PE Apoptosis detection kit was purchased from BD Biosciences and performed according to manufacturer's instructions.
Cell Treatment, Protein Isolation and ECL Western Blot Analysis
MCF10A and MCF7cells were plated at a density of 1.7 × 106/100 mm and upon reaching 75 to 80% confluency, the growth medium was removed and replaced with a serum-free, defined medium containing DMEM-F12, 100 ng/ml cholera toxin, 0.5 μg/ml of hydrocortisone, and 5 μg/ml of gentamycin sulfate for MCF10A, and MEM for MCF7. Cells were maintained in defined medium for 24 hour prior to the addition of ligand: human EGF (Invitrogen, USA), IGF-1 (Sigma, USA), insulin (Sigma, USA) and harvested at 10-20 min or 16 hr after the addition of ligand. The MEK inhibitor, U0126 (Calbiochem, USA), the Akt inhibitor, SH-6 (Axxora Platform, USA), the EGFR inhibitor, AG1478 (Sigma, USA), and the blocking antibody EGFR-mAb528 (Santa Cruz Biotechnology, USA) were added 30-60 min before addition of ligand. Cells harvested at 16 hr were sonicated in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 0.25% deoxycholate, 150 mM NaCl, 10 mM EGTA, 0.2% sodium dodecyl sulfate [SDS]) containing a protease inhibitor cocktail (Sigma, USA) and a phosphatase inhibitor I and II mixture (Sigma, USA). Aliquots of the lysates containing 100-200 μg of protein were boiled at 100°C for 10 min, electrophoresed on denaturing SDS-7% or 12% polyacrylamide minigels, and then transferred to polyvinylidene difluoride membranes (PVDF, Millipore, Bedford, Mass. USA). Blots were blocked 1-2 hr in TBST (20 mM Tris [pH 7.5], 150 mM NaCl, 0.5% Tween 20) containing 5% Carnation dry milk and then incubated with primary antibody for 1-2 hr (or overnight for antibodies directed against phospho-proteins) in TBST-1-5% carnation milk. Primary antibodies used were monoclonal and polyclonal anti-C/EBPβ (1:250, Santa Cruz, USA), polyclonal anti-GAPDH (1:5000, Trevigen, Gaithersburg, MD, USA), polyclonal β-actin (1:1000 Santa Cruz, USA), monoclonal anti-phospho-p44/42 (1:2000, Cell Signaling, Beverly, MA, USA), polyclonal anti-p44/42 (1:2000, Cell Signaling, USA), monoclonal anti-phospho Akt, polyclonal Akt (1:1000, Cell Signaling, USA), polyclonal anti-EGFR (1:1000 Santa Cruz, USA), monoclonal anti-phospho-EGFR (Tyr 845, 1:1000, Cell Signaling, USA). Blots were washed with TBST three times for 5 to 10 min each with agitation and then incubated for 1 hr with either goat anti-mouse-horseradish peroxidase (HRP) conjugate (Santa Cruz. USA) or goat-anti-rabbit-HRP (Bio-Rad, Hercules, CA, USA) in TBST-1-5% carnation. Proteins were visualized by either DURA or FEMTO chemiluminescence (Super Signal; Pierce, Rockford, Ill. USA) and HyBlot CL film (Denville Scientific, Metuchen, NJ, USA). Blots were stripped in Re-blot Plus Mild Solution (Chemicon, Temecula, CA, USA) for reprobing.
Western Blot Analysis Using Odyssey Infrared Imaging
Proteins were electrophoresed and transferred to PVDF membranes as described above. Membranes were blocked for 1 hr in Odyssey blocking buffer. Primary antibodies (1:250, monoclonal anti-C/EBPβ, Santa Cruz, USA), polyclonal anti-GAPDH (1:5000, Trevigen, Gaithersburg, MD, USA) and secondary antibodies (1:5000, goat anti-mouse IR Dye 800 CW, LI-COR Biosciences and 1:5000, goat anti-mouse IR Dye 680 DX, LI-COR, USA) were diluted in blocking buffer with 0.1% Tween-20 and incubated with the blot for 1 hr at room temperature. After washing, the membranes were scanned using Li-COR's Odyssey infrared imaging system and quantitated using Odyssey 3 software.
Quantitative Realtime PCR
MCF10A and MCF7cells were plated at a density of 75 to 80% confluency, the growth medium was removed and replaced with a serum-free, defined mediums as described. Cells were maintained in defined medium for 24 hour prior to the addition of human IGF-1 (Sigma, USA) and harvested at 16 hr after the addition of ligand by adding 1 ml Trizol (Invitrogen, USA). Total RNA was extracted according to the manufacturer's instruction. First-strand cDNA was prepared with 5 μg total RNA, random primers and reverse transcriptase (SuperScript II RNase H, Invitrogen, USA) according to the manufacturer's instruction. Quantitative PCR was performed by using real-time PCR iCycler (Bio-Rad, USA). PCR reaction and C/EBPβ primers were: sense 5' AACTCTCTGCTTCTCCCTCTG 3'; antisense 5'AAGCCCGTAGGAACATCTTT 3'. Ct values were converted to relative expression using the delta-delta Ct method, allowing normalization to both 18S and untreated control. The primer sequences for 18S were sense 5' GTAACCCGTTGAACCCCATTC 3'; antisense: CCATCCAATCGGTAGTAGCG 3'.
Luciferase Assay
To validate the activity of individual LIP and LAP2 constructs, a C/EBP consensus luciferase construct (500 ng) and a Renilla construct (20 ng) as internal control were cotransfected with LAP2 and LIP individually or together at different ratios into C/EBPβ null cells to a total of 2500 ng plasmid DNA. Control vector serves as both a control for basal activity and to match the quantity of plasmid DNA. Luciferase and Renilla activities were recorded at 48 hrs. For the IGF experiment, MCF-10A cells were cultured in Falcon 24-well plates and at 70% confluency, were transfected with a C/EBP consensus Luciferase construct (500 ng) and a Renilla construct (20 ng) as internal control. Transfection was conducted using Fugene reagent (Roche, Switzerland, according to manufacturer instructions) and cells were maintained in serum free medium for 24 hrs. The cells were then treated with 2.6 nM IGF-1 for 16 hrs in serum free medium and luciferase activity was analyzed at the end of treatment. The relative luciferase activity was calculated as Luciferase value/Renilla value. n = 5
Immunoprecipitation and Immuno-Blot Analysis of EGFR
MCF10A cells incubated with ligand for 10 min were extracted in RIPA buffer without SDS, and sonicated. Protein extracts (1 mg) were pre-cleared for 1 hr at 4°C with protein G-PLUS agarose (Santa Cruz, USA), then immunoprecipitated overnight at 4°C with anti-EGFR (1:1000, Santa Cruz, USA) or 4G10-conjugated agarose beads (Upstate Biotechnology, Waltham, MA, USA) to immunoprecipitate IGF-1R/IR. The beads were rinsed 3 times with RIPA (without SDS), sample buffer was added, the mixture boiled for 10 minutes followed by electrophoresis through SDS-7% polyacrylamide minigels, and transfer to PVDF. Immuno-blots were performed as above using anti-phospho-EGFR (1:1000, Cell Signaling, USA), anti-IR (1:1000 Upstate Biotechnology, USA) or anti-IGF-1R (1:1000 Upstate Biotechnology, USA).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HLL carried out the LIP/LAP ratio experiments, the anoikis studies, some of the inhibitor cell signaling studies and conducted the ErbB analysis. BRB generated the initial data which showed that IGF-1 and insulin regulates LIP expression and conducted some of the inhibitor cell signaling studies. CAZ participated in the design of all experiments, interpreted the data, conducted the statistical analyses and wrote the manuscript. All authors read and approved the final manuscript.